Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE Other stock markets 00:00:00 27/06/2026 +04			5-day change	1st Jan Change
3.040 ^USD	+1.33%		+3.05%	+10.55%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation	Visibility	Consensus
PERSPECTIVE THERAPEUTICS, INC.	347M	-	BBB	-	-
LONZA GROUP AG	46.2B		AAA
REVOLUTION MEDICINES, INC.	38.71B	-	B	-	-
IQVIA HOLDINGS INC.	31.9B		AAA
BEONE MEDICINES AG	31.12B		-
CELLTRION, INC.	23.77B		A
ASCENDIS PHARMA A/S	16.2B	-	-	-	-
MEDPACE HOLDINGS, INC.	15.05B		BBB
EUROFINS SCIENTIFIC SE	13.74B		AA
IONIS PHARMACEUTICALS, INC.	13.42B	-	A	-	-
ICON PUBLIC LIMITED COMPANY	13.01B		AAA
BIO-TECHNE CORPORATION	11.06B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	10.39B		AA
TEMPUS AI, INC.	10.08B		A		-
APOGEE THERAPEUTICS, INC.	9.93B	-	B	-	-
ALKERMES PLC	9.18B		A
PRAXIS PRECISION MEDICINES, INC.	9.14B	-	B	-	-
KYMERA THERAPEUTICS, INC.	8.89B	-	BBB	-	-
BLUEPRINT MEDICINES CORPORATION	8.38B	-	BB	-	-	-	-
QIAGEN N.V.	8.15B		AAA
Average	16.43B		A
Weighted average by Cap.			A